5-YEAR BDI-40 UP 108%, ASX200 DOWN 9%
July 7th 2011 00:26
Biotech Daily
Friday July 1, 2011
Daily news on ASX-listed biotechnology companies
Friday July 1, 2011
Daily news on ASX-listed biotechnology companies
Subscribe to Biotech Daily at the link above or at www.biotechdaily.com.au
BIOTECH DAILY’S TOP 40 INDEX
June 2011 was a bad month all around, for the ASX, the US and European markets and across most sectors, including the Biotech Daily Second 20 dragging down the Biotech Daily Top 40 Index (BDI-40) index 5.4 percent, but there is a much bigger picture.
The BDI-40 is five years old today and it is up 108.8 percent for the 60 months from the closing at June 30, 2006 to last night’s close. The S&P ASX200 is down 9.2 percent for the same period.
Biotech Daily was fortuitous in arriving as a raft of companies moved from phase I and II trials to phase III, registration and product in the market. While acquisitions removed Peplin, Arana and Chemgenex, the organic growth has been tremendous, and not restricted to Acrux, Mesoblast and Heartware, three of the stand-out success stories.
On July 1, 2006 Bionomics was worth $22 million and is now $191 million, Clinuvel is up from $65 million to $306 million, Starpharma $62 million to $372 million, Sunshine Heart $10 million to $51 million and Tissue Therapies is up 12-fold from $8 million to $97 million.
The hard luck stories include the deceased Ventracor, the rather poorly Progen and Avexa among others, with Biota close to recovery and Pharmaxis hopefully not far away.
For the year to June 30, 2011, the ASX200 was up 7.1 percent, but the BDI-40 was up 61.9 percent. The Second 20 companies had significant falls many from relatively low bases, but included losses by QRX, Anteo, Genetic Technologies and Phosphagenics. The BDI-20 was up 64.2 percent for the year.
The Big Caps of Cochlear, CSL and Resmed (which are not included in the BDI-40) fell 4.6 percent in June and were down 6.2 percent for the year to June 30.
In June the BDI-20 slipped 0.9 percent to a collective market capitalization of $6,553 million, the Second 20 was down 29.3 percent to $885 million, giving a fall of 5.4 percent to the BDI-40 for the month compared to the ASX200 down 2.1 percent for the month.
BDI-40 v ASX200 Jul 1, 2006 to Jul 1, 2011
Subscribe to Biotech Daily at the link above or at www.biotechdaily.com.au
| 28 |
| Vote |
Add To: 
subscribe to this blog